SOPHiA GENETICS SA (SOPH)

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. The company has a partnership with Synnovis to bring blood-based cancer testing to patients in the United Kingdom and a collaboration with AstraZeneca to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies. The company was incorporated in 2011 and is based in Rolle, Switzerland.

Ticker: SOPH
Exchange: Nasdaq
Sector: Healthcare
Industry: Health Information Services
Market cap: $611.60M
52-week range: $3.83 - $8.98

Valuation

Share price: $7.14 (close of Nov 6, 2026)
P/E (TTM): -6.55x
Price to book: 8.94x
Price to free cash flow: -14.73x
Enterprise value: $578.99M
Book value per share: $0.80

Price performance

Period	Change
1 day	+7.85%
5 days	-6.42%
1 month	-3.25%
3 months	+6.73%
6 months	+42.23%
Year to date	+52.89%
1 year	+50.63%
3 years	+84.97%
5 years	-54.05%
All time	-57.40%

Short interest

As of: Oct 15, 2026
Short % of float: 1.24%
Shares short: 1.00M
Days to cover: 1.45
Change since prior report: -10.77%
Source: FINRA consolidated short interest

Profitability and growth

Return on equity: -167.57%
Return on invested capital: -64.36%
Return on assets: -48.46%
Return on capital employed: -63.03%
Gross margin: 67.40%
Net margin: -102.24%
EBITDA margin: -86.62%
Revenue growth: 18.56%

Cash flow and balance sheet

Free cash flow yield (TTM): -6.79%
Current ratio: 2.29x
Net debt to EBITDA: 0.51x

Latest reported year

Period end: Dec 31, 2025
Fiscal year: 2025
Revenue: $77.27M
Cost of revenue: $25.19M
Gross profit: $52.08M
EBITDA: -$66.93M
Net income: -$79.00M
Earnings per share: $-1.17
Research and development: $34.22M
Shares outstanding: 67.54M

Income statement by year

Period end	Revenue	Gross profit	Net income	EPS
2025-12-31	$77.27M	$52.08M	-$79.00M	-$1.17
2024-12-31	$65.17M	$43.94M	-$62.49M	-$0.95
2023-12-31	$62.37M	$42.91M	-$78.98M	-$1.22
2022-12-31	$47.56M	$31.25M	-$87.45M	-$1.36
2021-12-31	$40.45M	$25.22M	-$73.67M	-$1.33
2020-12-31	$28.40M	$17.69M	-$39.34M	-$0.93
2019-12-31	$25.36M	$17.83M	-$33.79M	$0.00

Margins and returns by year

Period end	Gross margin	Net margin	Return on equity	Return on capital
2025-12-31	67.40%	-102.24%	-167.57%	-64.36%
2024-12-31	67.42%	-95.89%	-64.77%	-52.61%
2023-12-31	68.80%	-126.63%	-52.15%	-44.00%
2022-12-31	65.71%	-183.87%	-43.70%	-40.43%
2021-12-31	62.35%	-182.14%	-26.75%	-24.78%
2020-12-31	62.29%	-138.52%	-39.14%	-32.94%
2019-12-31	70.30%	-133.23%	-151.85%	-

Cash and debt by year

Period end	Cash	Debt
2025-12-31	$70.29M	$47.73M
2024-12-31	$80.23M	$13.24M
2023-12-31	$123.25M	-
2022-12-31	$161.31M	-
2021-12-31	$192.96M	-
2020-12-31	$74.63M	$457.00K
2019-12-31	$18.07M	-
2018-12-31	$53.91M	-

Free cash flow by year

Period end	Free cash flow	Stock-based compensation
2025-12-31	-$36.47M	$16.20M
2024-12-31	-$44.76M	$16.49M
2023-12-31	-$54.72M	$15.24M
2022-12-31	-$74.19M	$13.61M
2021-12-31	-$60.62M	$8.51M
2020-12-31	-$32.18M	$1.36M
2019-12-31	-$33.03M	$717.00K

Investor relations

Past earnings dates

Reported	Fiscal period	EPS estimate
2026-11-03	Sep 2026	-$0.13
2026-08-04	Jun 2026	-$0.15
2026-05-05	Mar 2026	-
2026-03-03	Dec 2025	-
2025-11-04	Sep 2025	-
2025-08-05	Jun 2025	-
2025-05-06	Mar 2025	-$0.21
2025-03-04	Dec 2024	-$0.24

Filings and sources

Company website: sophiagenetics.com
SEC filings: 10-K, 10-Q and 8-K on EDGAR
Earnings calendar: All upcoming reports

Similar companies

Veeva Systems Inc (VEEV) · HealthEquity, Inc. (HQY) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR) · Natera, Inc. (NTRA) · Agilent Technologies, Inc. (A) · IQVIA Holdings Inc. (IQV) · IDEXX Laboratories Inc (IDXX)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades